Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
ESTC Elastic NV
STKH Steakholder Foods Ltd
NHEL Natural Health Farm Holdings Inc
ICPT Intercept Pharmaceuticals Inc
BMY Bristol-Myers Squibb Co
DTCFF Defence Therapeutics Inc
ADBE Adobe Inc
FATP Fat Projects Acquisition Corp
LGVC LAMF Global Ventures I Corp
Go

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.

Price
Delayed
$550.76
Day's Change
-1.53 (-0.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
554.13
Day's Low
548.08
Volume
(Light)

Today's volume of 676,244 shares is on pace to be much lighter than LLY's 10-day average volume of 3,020,566 shares.

676,244

Display:

Providers:

UpdateCancel
All providers
Yesterday's News, September 25, 2023
Eli Lilly & Co. Stock Rises Monday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.32% higher to $552.29 Monday, on what proved to be an all-around positive trading session for...(MarketWatch)

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.(Zacks)

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.(Zacks)

September 22, 2023
Eli Lilly & Co. Stock Outperforms Market On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.07% higher to $550.54 Friday, on what proved to be an all-around dismal trading session for...(MarketWatch)

Eli Lilly, Boehringer Ingelheim's Jardiance gets FDA approval for chronic kidney disease

Eli Lilly & Co. (LLY) and Boehringer Ingelheim said Friday that the U.S. Food and Drug Administration has approved their blockbuster drug Jardiance, already used for heart failure and diabetes, as a treatment for adults with chronic...(MarketWatch)

US FDA approves Jardiance(R) for the treatment of adults with chronic kidney disease

-- Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) -- Jardiance(R) (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and...(PR Newswire)

Eli Lilly set to dominate obesity drug market into the next decade, analysts say

Eli Lilly & Co. (LLY) is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report late Thursday. Although Novo Nordisk (NVO), maker of Ozempic and Wegovy, is...(MarketWatch)

The Zacks Analyst Blog Highlights Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health

Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.(Zacks)

September 21, 2023
Eli Lilly & Co. Stock Falls Thursday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) shed 3.42% to $550.13 Thursday, on what proved to be an all-around rough trading session for the stock...(MarketWatch)

Top Research Reports for Eli Lilly, Toyota Motor, Accenture & Others

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).(Zacks)

September 20, 2023
Eli Lilly & Co. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) slumped 0.93% to $569.64 Wednesday, on what proved to be an all-around rough trading session for the...(MarketWatch)

Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

FinancialNewsMedia.com News Commentary The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for abuse deterrent formulation technology from the pharmaceutical...(PR Newswire)

September 19, 2023
Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $574.96, marking a +0.64% move from the previous day.(Zacks)

Eli Lilly & Co. Stock Rises Tuesday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.64% higher to $574.96 Tuesday, on what proved to be an all-around rough trading session for...(MarketWatch)

Thinking about trading options or stock in Palantir Technologies, Broadcom, Eli Lilly And Co, General Electric, or Taiwan Semiconductor?

InvestorsObserver issues critical PriceWatch Alerts for PLTR, AVGO, LLY, GE, and TSM. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.(Zacks)

September 18, 2023
Eli Lilly & Co. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) slipped 0.76% to $571.28 Monday, on what proved to be an all-around great trading session for the...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.